These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 31905382)

  • 1. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M
    J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts.
    Lukas M; Kolar M; Reissigova J; Duricova D; Machkova N; Hruba V; Lukas M; Vasatko M; Jirsa J; Pudilova K; Malickova K
    Scand J Gastroenterol; 2022 Jul; 57(7):814-824. PubMed ID: 35234552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW
    J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
    Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
    Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
    Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.
    Buer LC; Moum BA; Cvancarova M; Warren DJ; Medhus AW; Høivik ML
    J Crohns Colitis; 2017 Mar; 11(3):297-304. PubMed ID: 27660339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.
    Cingolani L; Barberio B; Zingone F; Ferronato A; Bertani L; Costa F; Bodini G; Demarzo MG; Melatti P; Gubbiotti A; Massimi D; Casadei C; D'Incà R; Savarino EV
    Sci Rep; 2021 May; 11(1):10368. PubMed ID: 33990652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
    Casanova MJ; Nantes Ó; Varela P; Vela-González M; Rivero M; Sierra-Gabarda O; Riestra S; Barreiro-de Acosta M; Martín-Rodríguez MDM; Gargallo-Puyuelo CJ; Reygosa C; Muñoz R; de la Filia-Molina IG; Núñez-Ortiz A; Kolle L; Calafat M; Huguet JM; Iglesias-Flores E; Martínez-Pérez TJ; Bosch O; Duque-Alcorta JM; Frago-Larramona S; Van Domselaar M; González-Cosano VM; Bujanda L; Rubio S; Mancebo A; Castro B; García-López S; de Francisco R; Nieto-García L; Laredo V; Gutiérrez-Casbas A; Mesonero F; Leo-Carnerero E; Cañete F; Ruiz L; Gros B; Del Moral-Martínez M; Rodríguez C; Chaparro M; Gisbert JP
    Aliment Pharmacol Ther; 2023 Jul; 58(1):60-70. PubMed ID: 37089065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
    Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
    J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J; Kaasen Jørgensen K
    Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
    Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
    Gonczi L; Vegh Z; Golovics PA; Rutka M; Gecse KB; Bor R; Farkas K; Szamosi T; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Papp M; Patai Á; Salamon Á; Tóth GT; Vincze Á; Biro E; Lovasz BD; Kurti Z; Szepes Z; Molnár T; Lakatos PL
    J Crohns Colitis; 2017 Jun; 11(6):697-705. PubMed ID: 27838610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.